1-7 of 7
W Knauf
Close
Sort by
Journal Articles

Bendamustine Plus Rituximab Versus CHOP Plus Rituximab in the First-Line Treatment of Patients with Indolent and Mantle Cell Lymphomas - First Interim Results of a Randomized Phase III Study of the StiL (Study Group Indolent Lymphomas, Germany).

Mathias J. Rummel, U. von Gruenhagen, N. Niederle, F. Rothmann, H. Ballo, E. Weidmann, M. Welslau, G. Heil, H. Duerk, M. Stauch, C. Losem, A. Matzdorff, C. Balser, K. Schalk, D. Kofahl-Krause, U. Kaiser, W. Knauf, A. Banat, D. Hoelzer, W. Brugger, on behalf of the StiL
Journal: Blood
Blood (2007) 110 (11): 385.
https://doi.org/10.1182/blood.V110.11.385.385
Published: 2007
Journal Articles

Uptake of New Therapeutics in the Treatment of Multiple Myeloma (MM) in Germany (GER) - Results from a Representative Multicentre Treatment Survey 2006.

Ralf Angermund, MD, W. Knauf, MD, M. Freund, MD, M. Nowrousian, MD, H. Einsele, MD, H. Goldschmidt, MD, W. Berdel, MD, W. Poenisch, MD, C. Straka, MD, L. Kellermann, H. Pliskat, PhD
Journal: Blood
Blood (2006) 108 (11): 5110.
https://doi.org/10.1182/blood.V108.11.5110.5110
Published: 2006
Journal Articles

Role of Bortezomib in the Treatment of Multiple Myeloma - First Results from a Representative Multicentre Treatment Survey in Germany (GER).

Ralf Angermund, W. Knauf, M. Freund, M. R. Nowrousian, H. Einsele, H. Goldschmidt, W. E. Berdel, W. Poenisch, C. Straka, L. Kellermann, S. Bammer
Journal: Blood
Blood (2005) 106 (11): 5156.
https://doi.org/10.1182/blood.V106.11.5156.5156
Published: 2005
Journal Articles

Treatment Situation for Newly Diagnosed Multiple Myeloma (MM) Patients in Germany (GER)- First Results from a Representative Multicentre Treatment Survey.

Mathias R.F. Freund, W. Knauf, H. Goldschmidt, H. Einsele, M. R. Nowrousian, W. E. Berdel, W. Poenisch, C. Straka, L. Kellermann, S. Bammer, R. Angermund
Journal: Blood
Blood (2005) 106 (11): 5158.
https://doi.org/10.1182/blood.V106.11.5158.5158
Published: 2005
Journal Articles

Cytogenetics and De Novo/Secondary AML but Not Age Are the Main Determinants for CR Rate and Hematological Recovery in Acute Myeloid Leukemia (AML) Using Intermediate Doses of Cytarabine (AraC) Delivered at the Presumptive Saturating Infusion Rate.

Cornelia Becker, MD, Haifa Al Ali, MD, Rainer Krahl, PhD, Wolfram Poenisch, MD, Dirk Hasenclever, PhD, Luisa Mantovani, MD, Mathias Freund, MD, R. Subert, MD, Ute Hegenbart, MD, Ulrich Wedding, MD, Johannes Meran, MD, Michael Herold, MD, Norma Peter, MD, W. Knauf, MD, Erika Kettner, MD, T. Ittel, MD, Astrid Franke, MD, K. Dachselt, MD, H.H. Wolf, MD, Ute Kreibich, MD, Manfred Schulze, MD, Michael Assmann, MD, Norbert Grobe, MD, Renate Huhn, MD, Ernst Zschuppe, MD, Veronika Schirmer, MD, U. Haak, MD, C. Klinkenstein, MD, B. Opitz, MD, Rita Pasold, MD, F. Fiedler, MD, C. Winkelmann, MD, Werner Helbig, MD, Dietger Niederwieser, MD
Journal: Blood
Blood (2005) 106 (11): 1851.
https://doi.org/10.1182/blood.V106.11.1851.1851
Published: 2005
Journal Articles

Activation of lymphocytes induced by recombinant human granulocyte- macrophage colony-stimulating factor in patients with malignant lymphoma

AD Ho, R Haas, G Wulf, W Knauf, R Ehrhardt, B Heilig, M Korbling, G Schulz, W Hunstein
Journal: Blood
Blood (1990) 75 (1): 203–212.
https://doi.org/10.1182/blood.V75.1.203.203
Published: 1990
Journal Articles

Disease-free survival after autologous bone marrow transplantation in patients with acute myelogenous leukemia

M Korbling, W Hunstein, TM Fliedner, S Cayeux, B Dorken, D Fehrentz, R Haas, AD Ho, U Keilholz, W Knauf
Journal: Blood
Blood (1989) 74 (6): 1898–1904.
https://doi.org/10.1182/blood.V74.6.1898.1898
Published: 1989